Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 7/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862249 | 0.88 | PTGES (0.41) | PTGESDHFRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL202444 | 0.88 | PTGES (0.41) | PTGESEGFRLMNAHPGDATM | |
| SCHEMBL3867941 | 0.87 | PTGES (0.41) | PTGESDHFRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3871117 | 0.87 | GSTM2 (0.41) | PTGESEGFRLMNAHPGDATM | |
| SCHEMBL3862358 | 0.86 | GSTM2 (0.42) | PTGESDHFRLMNAHPGDATM | |
| SCHEMBL3863530 | 0.85 | PTGES (0.39) | PTGESEGFRLMNA | |
| SCHEMBL3868943 | 0.84 | MAPT (0.43) | PTGESLMNAHPGDATM | |
| SCHEMBL3868941 | 0.84 | MAPT (0.43) | PTGESLMNAHPGDATM | |
| SCHEMBL3864107 | 0.84 | PTGES (0.40) | PTGESEGFRLMNAHPGDATM | |
| SCHEMBL3864103 | 0.84 | PTGES (0.40) | PTGESEGFRLMNAHPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | KAT2B 4166/4885STK17A 2780/4885PTGES 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.